At Paragon Biosciences, we do things differently. We begin with patients suffering from debilitating diseases with no effective treatment–children with fatal skin conditions; adults suffering episodes of paralysis, and other patient communities in search of a cure. The Paragon team has succeeded in getting 13 Novel Drug Approvals through the FDA , a success rate higher than most other peers in the U.S. healthcare sector.
We develop companies with disciplined, targeted strategies that address specific clinical areas.
Castle Creek Pharma employs a unique strategy that has made us one of the industry’s most prolific developers of innovative and high potential late stage assets for dermatological and ENT therapies identified as having the greatest medical need.
Precision is a research and development driven organization focused on developing complex treatments in rare genetic oncology diseases.
Harmony Biosciences is a biopharmaceutical company focused on identifying, developing, obtaining regulatory approval, and commercializing high-potential, innovative drugs to address unmet needs for patients with sleep and central nervous system (CNS) disorders.
Decade is a research and development company focused on novel Alzheimer’s disease therapeutics that will fundamentally improve patient outcomes and quality of life.
Pipelines of Paragon Companies
We have a diverse pipeline of investigational drugs in four therapeutic areas being tested in clinical trials across our family of companies.
Creatively and efficiently connecting resources and scientific expertise.
We partner with those who share our patient-first commitment to developing new medicines.
We believe it is our responsibility to contribute to organizations which improve the human experience, both globally and locally.
PARAGON IN THE NEWS
Paragon Biosciences Company Castle Creek Pharmaceuticals Receives Award from debra of America
Castle Creek Pharmaceuticals, a member of the Paragon Biosciences corporate family of companies, received the Partners in Progress Award at the 19th Annual debra of America (Systrophic Epidermolysis Bullosa Research Association of America) Benefit held October 26 in New York City.